# An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

> **NCT01854047** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 776 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** placebo
- **DRUG:** ICS/LABA therapy
- **DRUG:** Salbutamol/albuterol
- **DRUG:** Levosalbutamol/levalbuterol

## Key facts

- **NCT ID:** NCT01854047
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2014-11
- **Final completion:** 2015-04
- **Target enrollment:** 776 (ACTUAL)
- **Last updated:** 2017-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854047, "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01854047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*